{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:01:31Z","timestamp":1789052491640,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020732","name":"Innovative Research Team of High-level Local Universities in Shanghai","doi-asserted-by":"publisher","award":["SHSMU-ZDCX20211002"],"award-info":[{"award-number":["SHSMU-ZDCX20211002"]}],"id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430100"],"award-info":[{"award-number":["82430100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173407"],"award-info":[{"award-number":["82173407"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304001"],"award-info":[{"award-number":["82304001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102591","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T16:36:23Z","timestamp":1750696583000},"page":"102591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Immunotherapy for pemphigus and bullous pemphigoid"],"prefix":"10.1016","volume":"95","author":[{"given":"Chuqiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102591_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102591_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: a review in pemphigus vulgaris","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib3","article-title":"Pemphigus vulgaris and bullous pemphigoid: update on diagnosis and treatment","volume":"10","author":"Di Lernia","year":"2020","journal-title":"Dermatol Pr Concept"},{"key":"10.1016\/j.coi.2025.102591_bib4","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102591_sbref5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib6","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.jid.2024.02.029","article-title":"Single-cell profiling unveils the inflammatory heterogeneity within cutaneous lesions of bullous pemphigoid","volume":"144","author":"Ruan","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102591_sbref7","article-title":"Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102591_bib8","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.2938","article-title":"Skin eosinophil counts in bullous pemphigoid as a prognostic factor for disease severity and treatment response","volume":"103","author":"Baum","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coi.2025.102591_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/bjd.18364","article-title":"Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results","volume":"182","author":"Kamata","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.coi.2025.102591_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2020.1719833","article-title":"Epidemiology of major chronic inflammatory immune-related skin diseases in 2019","volume":"16","author":"Pezzolo","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2025.102591_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopeka","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib13","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102591_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102591_bib15","first-page":"379","article-title":"Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells","volume":"144","author":"Leuci","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102591_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coi.2025.102591_sbref20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamadermatol.2023.5679","article-title":"Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy","volume":"160","author":"Tedbirt","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib21","article-title":"Long-term real costs of a strategy using rituximab as first-line treatment for patients with moderate-to-severe pemphigus: evaluation from the French healthcare system","author":"Tedbirt","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102591_sbref22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2022.06.1187","article-title":"Clinical observation of different doses of rituximab for the treatment of severe pemphigus: a single-center prospective cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09546634.2019.1617831","article-title":"Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study","volume":"32","author":"Toosi","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.coi.2025.102591_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102591_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jid.2021.09.013","article-title":"Temporal outcomes after rituximab therapy for pemphigus vulgaris","volume":"142","author":"Tovanabutra","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib28","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/jdv.16561","article-title":"Long-term outcomes of rituximab therapy in pemphigus","volume":"34","author":"Shimanovich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102591_bib29","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaad.2020.12.062","article-title":"A 10-year retrospective cohort analysis of rituximab for the treatment of pemphigus in a Chinese population","volume":"85","author":"Chang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00403-018-1881-1","article-title":"Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?","volume":"311","author":"Balighi","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.coi.2025.102591_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107755","article-title":"Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study","volume":"96","author":"Aryanian","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coi.2025.102591_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15397","article-title":"Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: a retrospective cohort of 99 patients","volume":"35","author":"Nosrati","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102591_sbref33","article-title":"Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: a multi-centre cohort study","author":"Mao","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102591_bib34","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/1346-8138.17108","article-title":"Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab","volume":"51","author":"Zhang","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib36","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1111\/jdv.19133","article-title":"Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management","volume":"37","author":"de-la-Rosa-Fern\u00e1ndez","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102591_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdcr.2021.08.005","article-title":"Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy","volume":"16","author":"Benesh","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102591_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102591_bib39","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","article-title":"Safety, tolerability, and activity of ALXN1830 targeting the neonatal Fc receptor in chronic pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.18318","article-title":"Phase 2 BELIEVE study part B: efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris","author":"Murrell","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102591_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","article-title":"A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton\u2019s tyrosine kinase inhibitor, in pemphigus","volume":"103","author":"Yamagami","year":"2021","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coi.2025.102591_sbref44","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","article-title":"Efficacy and safety of rilzabrutinib in pemphigus: PEGASUS phase 3 randomized study","volume":"144","author":"Murrell","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102591_bib46","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102591_bib47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102591_bib50","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study","volume":"36","author":"Velin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102591_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109788","article-title":"Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review","volume":"116","author":"Liang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coi.2025.102591_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110050","article-title":"The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China","volume":"118","author":"Qi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coi.2025.102591_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.924","article-title":"Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: a preliminary study","volume":"11","author":"Hu","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.coi.2025.102591_bib54","article-title":"Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102591_bib55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/bjd\/ljad136","article-title":"Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients","volume":"189","author":"Moghadam","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib56","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jaad.2023.03.036","article-title":"Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: a multicenter retrospective review","volume":"89","author":"Learned","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib57","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.36849\/JDD.8258","article-title":"Treatment of bullous pemphigoid with dupilumab: a case series of 30 patients","volume":"23","author":"Miller","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib58","first-page":"694","article-title":"Fast itch relief during dupilumab predicts clinical efficacy in bullous pemphigoid: a retrospective cohort study","volume":"240","author":"Thevan","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.coi.2025.102591_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15727","article-title":"Severe pemphigoid nodularis successfully treated with dupilumab","volume":"35","author":"Jendoubi","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102591_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamadermatol.2023.4508","article-title":"Rituximab and omalizumab combination therapy for bullous pemphigoid","volume":"160","author":"Le","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102591_sbref61","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102591_bib62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.coi.2025.102591_bib63","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41590-023-01712-w","article-title":"Unraveling the diversity and functions of tissue-resident plasma cells","volume":"25","author":"Tellier","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2025.102591_sbref64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103128","article-title":"Integrative single-cell analysis reveals distinct adaptive immune signatures in the cutaneous lesions of pemphigus","volume":"142","author":"Xu","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102591_bib65","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102591_bib66","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102591_bib67","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102591_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:02:52Z","timestamp":1779084172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":68,"alternative-id":["S0952791525000676"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102591","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for pemphigus and bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102591"}}